Literature DB >> 34532097

Predictive values profiling of interleukin-2, interleukin-8, tumor necrosis factor-α, procalcitonin, and C-reactive protein in critical gastrointestinal cancer patients.

Yamin Yan1, Zhenghong Yu1, Jingjing Lu1, Peili Jin1, Zhaoqing Tang2, Yan Hu1.   

Abstract

BACKGROUND: The prognostic values of serum cytokines in cancer have not yet been fully determined. The objective of this study was to identify potential biomarkers associated with clinical outcomes in critical gastrointestinal (GI) cancer patients.
METHODS: A retrospective analysis was performed to quantify serum interleukin (IL)-2, IL-8, tumor necrosis factor-α (TNF-α), procalcitonin (PCT), and C-reactive protein (CRP) for correlation with clinical outcomes in GI cancer patients. The patients were divided into tertiles or quartiles based on the cytokine levels: Q1, Q2, and Q3, or Q1, Q2, Q3, and Q4. Receiver operating characteristic (ROC) curves were drawn to determine the optimal cutoff values of the cytokines.
RESULTS: Trend analysis showed that IL-2, IL-8, TNF-α, PCT, and CRP levels had significant positive correlations with mortality in GI cancer patients (all P-values were lower than 0.05). The significance was observed in Q3 vs. Q1 in IL-2 (P=0.026), Q3 vs. Q1 in IL-8 (P=0.003), Q2 and Q3 vs. Q1 in TNF-α (P=0.012 and P=0.002, respectively), Q4 vs. Q1 in PCT (P=0.031), Q3 and Q4 vs. Q1 in CRP (P=0.011 and P=0.001, respectively). The area under curve (AUC) of IL-2, IL-8, TNF-α, PCT, and CRP were 0.706, 0.729, 0.743, 0.769, and 0.736, and the optimal cutoff points were determined at 838 U/mL, 46.15 pg/mL, 11.95 pg/mL, 0.77 pg/mL, and 109.38 mg/L, respectively. Under these critical values, the sensitivity was 73.3%, 66.7%, 80.0%, 93.3%, and 86.7%, and the specificity was 64.9%, 72.0%, 60.4%, 61.8%, and 68.9%, respectively.
CONCLUSIONS: In GI cancer patients, serum IL-2, IL-8, TNF-α, PCT, and CRP levels can provide potential prognostic values for predicting clinical outcomes. The results may facilitate the exploration of cancer-related cytokine networks and development of novel therapy for GI cancer patients. 2021 Journal of Gastrointestinal Oncology. All rights reserved.

Entities:  

Keywords:  Cytokines; gastrointestinal cancer (GI cancer); prognostic value

Year:  2021        PMID: 34532097      PMCID: PMC8421898          DOI: 10.21037/jgo-21-334

Source DB:  PubMed          Journal:  J Gastrointest Oncol        ISSN: 2078-6891


  27 in total

Review 1.  Expression biomarkers for clinical efficacy and outcome prediction in cancer.

Authors:  Kathryn J Strand; Hanif Khalak; Jeffrey W Strovel; Reinhard Ebner; Meena Augustus
Journal:  Pharmacogenomics       Date:  2006-01       Impact factor: 2.533

Review 2.  Prognostic role of neutrophil-to-lymphocyte ratio in colorectal cancer: a systematic review and meta-analysis.

Authors:  Mu-Xing Li; Xue-Min Liu; Xu-Feng Zhang; Jian-Fei Zhang; Wan-Li Wang; Ying Zhu; Jian Dong; Ji-Wen Cheng; Zheng-Wen Liu; Le Ma; Yi Lv
Journal:  Int J Cancer       Date:  2014-01-29       Impact factor: 7.396

Review 3.  Cytokines in the Treatment of Cancer.

Authors:  Kevin C Conlon; Milos D Miljkovic; Thomas A Waldmann
Journal:  J Interferon Cytokine Res       Date:  2018-06-11       Impact factor: 2.607

Review 4.  Exercise training, circulating cytokine levels and immune function in cancer survivors: A meta-analysis.

Authors:  Nasim Khosravi; Lee Stoner; Vahid Farajivafa; Erik D Hanson
Journal:  Brain Behav Immun       Date:  2019-08-24       Impact factor: 7.217

Review 5.  Clinical outcome prediction by microRNAs in human cancer: a systematic review.

Authors:  Viswam S Nair; Lauren S Maeda; John P A Ioannidis
Journal:  J Natl Cancer Inst       Date:  2012-03-06       Impact factor: 13.506

6.  Postoperative Interleukin-6 Level and Early Detection of Complications After Elective Major Abdominal Surgery.

Authors:  Thijs C D Rettig; Lisa Verwijmeren; Ineke M Dijkstra; Djamila Boerma; Ewoudt M W van de Garde; Peter G Noordzij
Journal:  Ann Surg       Date:  2016-06       Impact factor: 12.969

7.  IL-6 and IL-11 as markers for tumor aggressiveness and prognosis in gastric adenocarcinoma patients without mutations in Gp130 subunits.

Authors:  Laura G Necula; Mihaela Chivu-Economescu; Elena L Stanciulescu; Coralia Bleotu; Simona O Dima; Irina Alexiu; Adriana Dumitru; Gabriel Constantinescu; Irinel Popescu; Carmen C Diaconu
Journal:  J Gastrointestin Liver Dis       Date:  2012-03       Impact factor: 2.008

Review 8.  Cytokine networks and their association with Helicobacter pylori infection in gastric carcinoma.

Authors:  Vahid Bagheri; Bahram Memar; Amir Abbas Momtazi; Amirhossein Sahebkar; Mehran Gholamin; Mohammad Reza Abbaszadegan
Journal:  J Cell Physiol       Date:  2017-03-07       Impact factor: 6.384

9.  Interleukin-6 blood level is associated with circulating carcinoembryonic antigen and prognosis in patients with colorectal cancer.

Authors:  C Belluco; D Nitti; M Frantz; P Toppan; D Basso; M Plebani; M Lise; J M Jessup
Journal:  Ann Surg Oncol       Date:  2000-03       Impact factor: 5.344

10.  The predictive prognostic values of serum interleukin-2, interleukin-6, interleukin-8, tumor necrosis factor-α, and procalcitonin in surgical intensive care unit patients.

Authors:  Yamin Yan; Yan Hu; Xiaorong Wang; Zhenghong Yu; Yingjia Tang; Yuxia Zhang; Wenyan Pan
Journal:  Ann Transl Med       Date:  2021-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.